Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adagene ( (ADAG) ) has issued an update.
On April 1, 2026, Adagene reported its full-year 2025 results, highlighting encouraging clinical data for muzastotug plus pembrolizumab in microsatellite stable colorectal cancer, including a 29% confirmed response rate at 20 mg/kg and median overall survival of 19.4 months at 10 mg/kg with favorable tolerability across 67 patients. The company is enrolling ahead of plan in a randomized Phase 2 dose-optimization study that is expected to support a registrational trial, while upcoming AACR 2026 presentations, expanded triplet-combination programs, and collaborations with Sanofi, Roche, Exelixis, and others, alongside $74.5 million in year-end 2025 cash and an extended runway into early 2028, reinforce Adagene’s positioning as a key player in next-generation immuno-oncology combinations.
Adagene’s 2025 financials showed net revenue surging to $7.7 million from $0.1 million a year earlier, driven by collaboration and licensing milestones, while R&D spending fell to $22.0 million and bank borrowings in China were reduced, signaling tighter cost control and reduced leverage. Taken together, the maturing survival data, de-risked dose selection strategy under FDA Project Optimus, robust partnership activity, and strengthened balance sheet suggest a clearer path toward late-stage development of muzastotug and potential value creation for shareholders if forthcoming readouts in 2026–2027 are positive.
The most recent analyst rating on (ADAG) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.
Spark’s Take on ADAG Stock
According to Spark, TipRanks’ AI Analyst, ADAG is a Neutral.
The score is held back primarily by very weak financial performance (sharp revenue decline, large losses, and negative/worsening cash flows). Technicals are a key offset with an established uptrend and positive momentum, while valuation remains constrained by negative earnings and no stated dividend yield.
To see Spark’s full report on ADAG stock, click here.
More about Adagene
Adagene Inc. is a platform-driven, clinical-stage biotechnology company listed on Nasdaq that focuses on discovering and developing novel antibody-based cancer therapies. The company’s lead asset, muzastotug (ADG126), is a masked anti-CTLA-4 antibody being advanced primarily in microsatellite stable colorectal cancer and hepatocellular carcinoma, supported by its proprietary SAFEbody masking technology and multiple big-pharma collaborations.
Average Trading Volume: 187,429
Technical Sentiment Signal: Buy
Current Market Cap: $184.8M
For an in-depth examination of ADAG stock, go to TipRanks’ Overview page.